|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
Our data are consistent with the hypothesis that MCP-1 is involved in the pathogenesis of human atherosclerosis and myocardial infarction.
|
16116069 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
NP-mediated 7ND gene delivery inhibited MCP-1-induced chemotaxis of mouse peritoneal macrophage ex vivo, which may be applicable for the treatment of atherosclerotic cardiovascular disease.
|
22023473 |
2011 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) is a potent agonist for mononuclear leukocytes and has been implicated in the pathogenesis of atherosclerosis and granulomatous lung disease.
|
9366570 |
1997 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1), as a critical factor for monocyte infiltration, is known to play a role in the development of atherosclerosis.
|
26354107 |
2016 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggest that MCP-1 blocking may be crucial in preventing the endothelial dysfunction induced by contrast medium in patients with inflammatory disease and atherosclerosis.
|
30918133 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this work, we synthesized monocyte-targeting iron oxide magnetic nanoparticles (MNPs), which were incorporated with the peptides derived from the chemokine receptor C-C chemokine receptor type 2 (CCR2)-binding motif of monocytes chemoattractant protein-1 (MCP-1) as a diagnostic tool for potential atherosclerosis.
|
29795012 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects.
|
12928151 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although plasma/serum levels of certain chemokines (eg, interleukin- 8/CXCL8 and monocyte chemoattractant protein-1/CCL2) have shown to be predictive for future cardiac events in some studies, their role as clinical biomarkers is unclear, and their ability to predict subclinical atherosclerosis has been disappointing.
|
18669888 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies indicate that chemokine CC-motif ligand 2 (CCL2) is involved in inflammation and atherosclerosis.
|
29864522 |
2018 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, serum MCP-1 and VE-cadherin levels were correlated with atherosclerosis and the stability of atherosclerotic plaques in patients with cerebral infarction.
|
28272702 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma MCP-1 concentration is genetically determined and associated with age and smoking habit and it also correlates with subclinical atherosclerosis in HIV-infected patients.
|
16445900 |
2006 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results support the premise that MCP-1 is secreted by VSMC in atherosclerotic plaques as well as by endothelial cells and macrophages and contributes to the pathogenesis of atherosclerosis.
|
8580375 |
1995 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, ghrelin can inhibit intraplaque angiogenesis and promote plaque stability by down-regulating VEGF and VEGFR2 expression, inhibiting the plaque content of macrophages, and reducing MCP-1 expression at an advanced stage of atherosclerosis in rabbits.
|
28189525 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The most promising anti-inflammatory compounds for treatment of atherosclerosis include non-specific anti-inflammatory drugs, phospholipase inhibitors, blockers of major inflammatory cytokines, leukotrienes, adhesion molecules, and pro-inflammatory signaling pathways, such as CCL2-CCR2 axis or p38 MAPK pathway.
|
29378168 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The 'M3' chemokine binding protein inactivates key chemokines involved in atherosclerosis (e.g.CCL2, CCL5 and CX3CL1).
|
28282403 |
2017 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that Hcy-induced ROS upregulate the expression and translocation of Ref-1 via NADPH oxidase, and then Ref-1 increases NF-kappaB activity and MCP-1 secretion in human monocytes/macrophages, which may accelerate the development of atherosclerosis.
|
17045925 |
2006 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In predialysis stage 3-5 diabetic and nondiabetic CKD patients, CAVI levels and its relation to atherosclerosis-associated risk factors including monocyte-chemoattractant protein-1 (MCP-1), sclerostin, fibroblast growth factor-23 (FGF-23), Klotho, and 25-OH vitamin D were determined.
|
31773386 |
2020 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data are consistent with the hypothesis that the genetic background of the host is involved in CCL2 production and that this chemokine is implicated in promoting metabolic disturbances and sub-clinical atherosclerosis in HIV-infected patients.
|
20573518 |
2010 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings clearly indicate the role of C/EBPs in the mechanism of upregulation of CCL2, an inflammation-related protein, observed in the hyperinsulinaemic state, which may initiate the process of atherosclerosis.
|
17180354 |
2007 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine at multiple phases of atherosclerosis in animals, but human studies are few and inconsistent.
|
25786118 |
2015 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Infection with an adenovirus delivering the EMMPRIN-siRNA ameliorated AS, promoted macrophage autophagy in plaques and reduced the serum TNF-α, IL-6, MCP-1 and NF-κB expression levels in the AS mice.
|
29154780 |
2018 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Screening of a panel of cytokines relevant to atherosclerosis revealed that 6-MP robustly inhibits monocyte chemoattractant chemokine-1 (MCP-1) expression in macrophages stimulated with lipopolysaccharide (LPS).
|
20413732 |
2010 |
|
Atherosclerosis
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, 7,8,4'-THI significantly downregulated TNF-α stimulated the expression of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 and phosphorylation of IκB kinase and IκBα involved in the initiation of atherosclerosis in HUVECs.
|
28946319 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A three-dimensional in vitro model to demonstrate the haptotactic effect of monocyte chemoattractant protein-1 on atherosclerosis-associated monocyte migration.
|
28041913 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previously, Matrix metalloproteinase-9 (MMP-9), monocyte chemotactic protein-1 (MCP-1) and toll-like receptor 4 (TLR4) were confirmed to play an important role in atherosclerosis and plaque instability.
|
28957799 |
2017 |